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                                                       ABSTRACT 
INTRODUCTION: 
               In an adult human, hypoglycaemia causes physiological responses in the 
form of autonomic activation, principally of the Sympatho-adrenal system, and 
results in secretion of adrenaline and end-organ stimulation. Blood supply is 
increased to the myocardium, the brain, the splanchnic circulation.  
                             The following hemodynamic changes will occur in our body 
such as elevation of heart rate and peripheral systolic Bp, a fall in central blood 
pressure, decrease in peripheral arterial resistance, and increased myocardial 
contractility, stroke volume, and cardiac output due to hypoglycaemia. The 
workload of the heart is temporarily increased. Patients with normal cardiovascular 
system can tolerate this transient cardiac stress. But patients who are all having 
DM and other risk factors cannot tolerate this transient myocardial stress and 
develop complications like arrhythmias and sudden cardiac cardiac death. 
                   In non-diabetic individuals arteries will be more elastic during 
hypoglycaemic state with decline in arterial wall stiff ness. But patients with 
diabetes, arterial wall stiffness is greater and arteries will become less elastic 
during hypoglycaemia. These changes cause hemodynamic abnormality like lesser 
fall in central aortic pressure. This progressive stiffness of arterial wall reduces 
myocardial perfusion and promotes myocardial ischemia.  
                        Hypoglycaemia causes ST Segment changes and lengthening of Q-
T interval and cardiac repolarisation abnormalities. This causes in coordinated 
contraction of cardiac muscles. Profuse release of catecholamine causes 
hypokalaemia. All these changes causes cardiac rhythm abnormality such as 
ventricular tachycardia, atrial fibrillation. 
             The increased sympathetic activity and concurrent secretion of hormones 
like endothelin causes vasoconstriction abnormalities in viscosity. 
          Viscosity - Increased erythrocyte concentration. 
           Coagulation-platelet activation, raise in factor VIII, von willebrand factor 
          Endothelial dysfunction-increase in CRP. 
These changes promote intravascular coagulation and thrombosis.  
 
 
 
 
 
 AIMS AND OBJECTIVES OF THE STUDY: 
                                  To assess the corrected Q-T interval during hypoglycemic 
episodes in diabetic patients with respect to their baseline characteristics- sex, 
Type of Diabetes, duration of Diabetes. 
 
                           MATERIALS AND METHODS 
 
SELECTION OF STUDY SUBJECTS: 
                             This study is to be conducted in diabetic patients who are all 
admitted in medical ward with symptoms of severe hypoglycemia at Govt. Rajaji 
Hospital, Madurai. Severe hypoglycaemia was defined in this study, as the condition 
requiring active medical intervention such as carbohydrate administration when 
plasma sugar level was <60 mg/dl. I categorise the patients into 4 groups according to 
their blood sugar levels. Cat I—60-50 mg/dl, Cat II—40-50 mg/dl,  
Cat III—30-40mg/dl, Cat IV--<30 mg/dl 
 
 STUDY POPULATION: 
                                       100 cases 
 
 
RESULTS: 
                      Out of 100 cases 75 patients developed Q-T c prolongation. 24 
patients from Cat-1& 2 and 51 patients from Cat-3&4 are developed Q-T 
prolongation in our study with significant p value of .048. In our study 448 ms was 
a mean Q-T interval in Cat I. As the blood sugar level decreases Q-T prolongation 
increases up to 519 ms in Cat IV. P value-0.001 
 
                                 In our study 4 patients in Category -III ,6 patients in Category- 
IV developed arrhythmias with statistically significant P value of   0.010. Chi 
square value-6.67 
.                               In our study 5 patients were died due to arrhythmias in 
Category -IV and 1 patient died in Category- III. There were no deaths observed in 
Category I&II with statistically significant P value of 0.047. 
 
 
 
 
 
 
                                          CONCLUSION 
   From our study we conclude, that     
                  Incidence of QTc prolongation is more with severe 
hypoglycemia. Q-T c interval more than 500millisecond causes 
Arrhythmia, thereby causing sudden cardiac death. Repolarization 
abnormality is the most common cause of arrhythmia in severe 
hypoglycemia (1). Deaths due to severe hypoglycemia are most common 
in type 2 Diabetes Mellitus patients.  Duration of diabetes mellitus is also 
a risk factor for developing arrhythmia and sudden cardiac death (19) 
 
KEY WORDS: Q-T prolongation, Repolarization abnormalities, Arrhythmias, 
Hypoglycemia 
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                                   INTRODUCTION 
 
                        In an adult human, hypoglycaemia causes physiological 
responses in the form of autonomic activation, principally of the Sympatho-
adrenal system, and results in secretion of adrenaline and end-organ 
stimulation. Blood supply is increased to the myocardium, the brain, the 
splanchnic circulation.  
                             The following hemodynamic changes will occur in our body 
such as elevation of heart rate and peripheral systolic Bp, a fall in central 
blood pressure, decrease in peripheral arterial resistance, and increased 
myocardial contractility, stroke volume, and cardiac output due to 
hypoglycaemia. The workload of the heart is temporarily increased. Patients 
with normal cardiovascular system can tolerate this transient cardiac stress. 
But patients who are all having DM and other risk factors cannot tolerate this 
transient myocardial stress and develop complications like arrhythmias and 
sudden cardiac cardiac death. 
                   In non-diabetic individuals arteries will be more elastic during 
hypoglycaemic state with decline in arterial wall stiff ness. But patients with 
diabetes, arterial wall stiffness is greater and arteries will become less elastic 
during hypoglycaemia. These changes cause hemodynamic abnormality like 
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lesser fall in central aortic pressure. This progressive stiffness of arterial wall 
reduces myocardial perfusion and promotes myocardial ischemia.  
                        Hypoglycaemia causes ST Segment changes and lengthening 
of Q-T interval and cardiac repolarisation abnormalities. This causes in 
coordinated contraction of cardiac muscles. Profuse release of catecholamine 
causes hypokalaemia. All these changes causes cardiac rhythm abnormality 
such as ventricular tachycardia, atrial fibrillation. 
             The increased sympathetic activity and concurrent secretion of 
hormones like endothelin causes vasoconstriction abnormalities in viscosity. 
          Viscosity - Increased erythrocyte concentration. 
           Coagulation-platelet activation, raise in factor VIII, von willebrand 
factor 
          Endothelial dysfunction-increase in CRP. 
These changes promote intravascular coagulation and thrombosis.  
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                           AIMS AND OBJECTIVES 
The study was done 
1) To assess the corrected Q-T interval during hypoglycemic episodes 
in diabetic patients with respect to their baseline characteristics- sex, 
Type of Diabetes, duration of Diabetes. 
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DEFINITION DIABETES MELLITUS: 
                                           Diabetes mellitus is a group of metabolic disorders 
characterized by chronic hyperglycemia associate with altered carbohydrates, 
Fat and protein metabolism due to absolute or relative deficiency of insulin 
secretion and or action. 
 
DEFINITION OF HYPOGLYCEMIA: 
                             AMERICAN DIABETES ASSOCIATION group on 
hypoglycemia in diabetes as “all episodes of abnormally low plasma sugar 
concentration that expose the individual to potential harm”. 
 
DEFINITION OF HYPOGLYCEMIA IN OUR STUDY:  
                                                   Hypoglycaemia was defined in this study, as the 
condition requiring active medical intervention such as carbohydrate 
administration when plasma glucose level was <60 mg/dl. 
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CLASSIFICATION OF DIABETES -AMERICAN DIABETES ASSOCIATION 
Types of diabetes mellitus 
(Etiologic classification of diabetes mellitus) 
Type1: 
     Beta cell destruction usually leading to absolute insulin deficiency 
a)autoimmune 
b)idiopathic 
type 2: 
a) primary defect - insulin resistance 
b) primary defect -  insulin secretion 
other specific types of diabetes: 
a) Genetic defects of beta cell dysfunction, e.g. MODY 1 to 6 
b) Genetic defects in insulin action, e.g. type A insulin resistance 
c) Diseases of exocrine pancreas, e.g. fibro calculus pancreatopathy 
d) Endocrinopthies, e.g.  acromegaly, cushings etc., 
e) Drugs or chemical – induced, e.g. glucocorticoids 
f) Infections, e.g., congenital rubella 
g) Uncommon forms of immune-mediated diabetes, e.g. Stiff Man 
Syndrome 
h) Other genetic syndromes 
GESTATIONAL DIABETES 
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STAGES OF DIABETES: 
     Stages 
 
 
 
 
 
Types 
Normo 
glycaemia 
Hyperglycemia 
Normal 
glucose 
regulation 
 
 
Impaired 
glucose 
tolerance 
Or 
Impaired 
fasting 
glucose 
Diabetes mellitus 
 
Not Insulin  Insulin           Insulin 
requiring    requiring       requiring  
                For control   for survival 
Type 1* 
Type 2 
Other 
specific 
types** 
   
Gestational 
Diabetes 
   
 Disorders of glycaemia; Etiologic types and stages 
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                                  TYPES OF DIABETES MELLITUS 
Type I DM: 
 Onset – childhood, adolescence, but can occurs at any age. 
 Auto immune destruction of β cells 
 IA – auto antibodies against islet cells, GAD, IA-2, IA-2B, insulin auto 
antibodies. They are more prone to develop following diseases, 
 Pernicious Anemia. 
Addison’s disease 
Grave’s disease,  
 Vitiligo,  
Thyroiditis,  
  IB – idiopathic 
        - Type 1 DM associated with HCA-B8-DR3-and/orDR4.Absent or 
poor response of glucose stimulated C-peptide levels are diagnostic of type-I 
diabetes. 
TYPE 2: 
 -Onset -Middle age or after 40 yrs 
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 -Here the basic Pathology is a combination of impaired β cell function, 
with marked increased in Peripheral Insulin resistance at receptor with raised 
liver glucose output production.  
        Coma is rare in type 2 DM, but which may result from hyperglycemia 
and hyper osmolality 
 
Other specific type (secondary diabetes): 
a) Genetic defect of β cell function: 
-onset of type-2 diabetes below 25yrs of age classified as MODY 
-Inherited through autosomal dominant gene 
-They do not have ICA antibodies and are not HLA-DR3 heterozygote 
-Glucokinase deficiency is a marker of MODY. 
-They are less prone to develop micro and macro vascular complications 
-Usually they don’t need insulin for diabetic control for varying period from 
the time of diagnosis 
 b) Genetic defects in Insulin action e.g.: (type A insulin resistance) 
              It is associated with Congenital or Acquired Syndromes, like 
Leprechaunism, lipoatrophy, Acanthosis Nigricans. 
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DISEASES OF EXOCRINE PANCREAS: 
                       Malnutrition related DM is a type of Diabetes, which is 
restricted to tropical countries 
DIAGNOSTIC CRITERIA OF MRDM: 
1) Age of onset <30 yrs. 
2) BMI < 19 
3) People living in tropics 
4) Variable exocrine pancreatic deficiency 
5) Requiring high doses of insulin 
6) Lack of proneness to ketosis in the absence of stressful situation. 
There are 2sub types: 
1) Fibro calculus Pancreatic Diabetes 
2) Protein Deficient Diabetes Mellitus 
Etiology of FCPO: 
-Incidence is around <1% of Indian population 
-Dietary toxins, genetic susceptibility and malnutrition are the causes of 
FCPO 
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Classical triad FCPO: 
1) Diabetes 
2) Recurrent abdominal pain. 
3) Pancreatic Calculi 
PDDM: 
     -This condition usually affect malnourished young patients. 
     -Wasting and stunting are the clinical indicators of malnutrition. 
     -Pancreatic calcification is not seen in that group. 
Endocrinopathies: 
                  -DM may be associated pituitary, adrenal, thyroid glands and 
gonads dysfunction. Overt diabetes mellitus can occur in acromegalics, 
diabetes occurring in a Cushing’s disease resolves with effective treatment. 
Schmidt’s syndrome is an autosomal recessive condition that usually 
associates with type1 DM, thyroiditis and failure of adrenal glands. 
Drugs or chemical induced:  
1) Glucocorticoids 
2) ACTH  
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3) Thiazide diuretics 
4) Phenytoin 
5) Pentamidine 
6) Vacor 
Other genetic syndromes: 
1) Down’s syndrome 
2) Turner’s syndrome 
3) Kleinfelter syndrome 
4) Alstroms 
5)  Lawrence moon biedel 
6) Prader willi syndrome 
7) Dystrophia myotonica 
 
4. Gestational diabetes mellitus: 
    It is defined as glucose intolerance in pregnant individual. 
                            In a postpartum period they may revert back to normal or 
continue to have impaired glucose tolerance or may become frank diabetes. 
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Fetus of diabetic mother have many diabetic related complications like 
hypoglycemia, hyper bilirubinemia, hypocalcaemia, macrosomia in the early 
neonatal period. 
Baby born to diabetic mother may prone to develop diabetes in the later part 
of life 
 Impaired glucose tolerance: 
                   - It represents transient stage between normal glucose tolerance 
and type 2 DM 
                - 2 HR PG 140-199mg/dl 
Impaired fasting glucose: 
                - Stage of impaired glucose homeostasis   
                - FBS = 100 – 125 mg/dl 
                - 2HR PG = < 140 mg/dl 
Combined glucose tolerance: 
- They have both IFG and IGF. 
- Both insulin resistance and impaired insulin secretion 
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Metabolic characteristics: 
                              IGT&IFT have raised sugar levels in first 60 mts. IGT 
represents defective second phase insulin secretion.so continues to raise after 
60 mts and remains elevated at 120 mts. 
                  IFG starts with high FPG  due to hepatic insulin resistance, but the 
incremental raise in plasma glucose at 30 – 60 mts is only slightly greater than 
normal glucose tolerant individuals. By 120 mts plasma sugar level will come 
to normal.  IGT=> impaired second phase of insulin secretion and muscle 
insulin resistance resulting in less disposal of glucose during OGTT. 
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IFT IGT 
 
 Reduced hepatic insulin 
sensitivity 
 Stationary beta cell 
dysfunction and /or 
 Chronic low beta cell mass 
 Altered GLP-1 secretion 
 Inappropriately elevated 
glucagon secretion 
 
 
 
 
 Reduced peripheral insulin 
sensitivity 
 Near – normal hepatic 
insulin sensitivity 
 Progressive dysfunction of 
beta cell function 
 Reduced secretion of GIP 
and 
 Inappropriately elevated 
glucagon secretion 
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CRITERIA FOR DIAGNOSIS OF DIABETES: 
1. HbA1c >6.5% the test should be performed in a laboratory using a 
method that is NGSP certified and standardized to the DCCT assay  
OR 
2. FPG>126mg/dl (7.0mmol/L) .fasting is defined as no caloric intake for 
at least 8 hours 
OR  
2Hour plasma glucose ≥ 200 mg/dl during an OGTT. The test should be 
performed as described by WHO using a glucose load containing the 
equivalent of 75g anhydrous glucose dissolved in water  
OR 
In a patient with classic symptoms of hyper glycaemia or hyperglycemic 
crisis, a random plasma glucose ≥ 200mg/dl (11.1mmol/l) 
    
 
 
 
  
 
[24] 
 
 
                                  
 
Characteristics     Type 1 DM MODY Type 2 DM in children 
 
onset of age Peak at 5 & 15 
years 
<25 years Teenage years 
Ethnic group Caucasians Caucasians Hispanic, Asians, 
African American 
Mexican – America, 
Male : female 1.1:1 1:1 1:1.5 
Islet cell auto immunity Present Absent Absent 
HLA DR3, DR4 Very common No increased 
frequency 
No increased frequency 
DKA Common Rare Uncommon 
Prevalence of obesity Uncommon Uncommon ≥90% 
Mode of inheritance Non 
mendalian, 
generally 
sporadic 
Autosomal 
dominant 
Non mendalian, but 
strongly familial 
Number of genes controlling 
inheritance 
Polygenic Monogenic Polygenic 
Pathogenesis Autoimmune 
beta cell 
destruction 
Insulinopenia Insulin resistance plus 
insulinopenia. 
Long term course Insulin 
dependent 
Non-insulin 
dependent 
Non-insulin dependent 
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EPIDEMIOLOGY OF DIABETES 
Global burden of diabetes: 
   1)  In 2012 371 million people had diabetes. The numbers to increase to 550 
million by 2030.  
2) There is a rising incidence of type 2 DM globally.  
3) 80% of diabetic subjects live in low and middle income countries.  
4) Greatest number of people with diabetes are between 40 – 59 years of age.  
5) Almost 50% diabetics are undiagnosed. Diabetes causes 4.6 million death 
in 2011. 
6) 78000 children develop type1 diabetes every year 
Common form of diabetes and their prevalence: 
Diabetes Prevalence 
Type1 ~ 5% 
Type2 ~95% 
Gestational 2 – 10 % of all pregnant women 
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Geographical distribution of Diabetes: 
State  Author, year  Prevalence 
North  
Kashmir 
New Delhi 
New Delhi 
 
West 
Mumbai  
Jaipur 
 
East 
Guwahati 
Kolkata 
 
South 
Thiruvanthapuram 
Hyderabad 
Bangalore 
Chennai 
 
Ernakulum 
Vellore 
Tamilnadu 
 
 
 
 
 
 
 
 
 
 
 
 
 
Zargar et al. 2000 
Prabakaran et al. 2005 
Ramachandran et al. 
2005 
 
 
Ramachandran et al. 
2001 
Gupta et al. 2003 
 
 
Shaw et al.1999 
Ramachandran et al. 
2001 
 
  
Raman et al. 1999 
Ramachandran et al. 
2001 
Ramachandran et al. 
2001 
Ramachandran et al. 
2001 
Mohan et al. 2006 
Menon et al.2006 
Ragupathi et al. 2007 
Ramachandran et al. 
2008 
 
 
 
 
6.1% 
15% 
10.3% 
 
 
 
9.3 
8.6 
 
 
 
8.3 
11.1 
 
 
 
16.3 
16.6 
 
12.4 
 
13.5 
 
14.3 
19.5 
3.7 
18.6 
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PATHOGENESIS OF TYPE 1 DM: 
1) Auto Immune destruction: 
 Infiltration of lymphocytes in pancreatic beta cells causes type 1 DM 
o  After all beta cells are destroyed, the islets  cells become atrophic 
o  deficiency of insulin secretion will occur due to immune mediated 
destruction of  beta cells  
  
                    PATHOGENESIS OF TYPE1 DM 
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o pancreatic α-cells is also abnormal in type 1 DM 
o There is excessive secretion of glucagon in type 1 DM patients. 
Normally, hyperglycemia leads to reduced glucagon secretion.  
o So in patients with type 1 DM patients glucagon secretion is not 
suppressed by elevated blood sugar level 
 Abnormal level of glucagon worsen the metabolic derangements due to 
insulin deficiency. 
 Genetic considerations in Type 1 DM: 
o Risk of diabetes is more with children born to diabetic parents 
o Risk is around 3% when mother is affected, and is around 6% when 
father is affected 
o Approximate empirical risk of development of type 1 DM up to the age 
of 25 years 
First-degree relative with type1 DM Risk of type 1 DM % 
Father 
Mother 
Both parents 
Mother and sibling 
Sibling 
Monozygotic twin 
 
2.5 
1.5 
15 – 20 
13 
3 
40 
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TYPE1 DIABETES MELLITUS-AN OVERVIEW OF ETIOLOGY 
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Pathology of Type 2 DM: 
o Type 2 DM is defined by  insulin resistance, abnormal insulin secretion  
that leads to abnormal fat metabolism and excessive hepatic glucose 
production, 
o  Pancreatic beta cells increase the insulin secretion to maintain the 
glucose tolerance in a near normal state in the early stage of this 
disorder. 
                            As insulin resistance and compensatory hyperinsulinemia 
progress, the pancreatic islets in certain individuals are unable to sustain the 
hyperinsulinemic state. Then patient will develop IGT. A further decline in 
insulin secretion and an increase in hepatic glucose production lead to overt 
diabetes with fasting hyperglycemia. 
                      
               PATHOGENESIS OF TYPE 2 DM 
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Insulin resistance: 
o Insulin resistance is a state in which a given concentration of insulin 
produces a less-than-expected biological effect.  
o Insulin resistance has also been defined as the requirement of 200 or 
more units of insulin per day to attain glycemic control and to prevent 
ketosis. 
o Insulin resistance results from inherited and acquired influences. 
Causes of Insulin resistance: 
• Pre receptor: 
– Anti-insulin antibodies 
– Abnormal insulin 
• Receptor: 
– Reduced  number of receptors 
–  Insulin receptor – blocking antibodies  
– Insulin receptor mutations 
– Reduced binding of insulin 
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• Post receptor: 
– Mutations of GLUT4 
– Abnormal  signal transduction 
Combinations of defects: 
                     Obesity is usually associated with post receptor 
abnormality and decreased number of insulin receptors. It is the 
common cause of insulin resistance. 
Aging: 
                            Aging is one the cause of insulin resistance - reduced 
production of GLUT-4 transporters 
RISK FACTORS: 
•  Hypertension (BP >140/90 mmHg)  
• History of GDM or delivery of baby >4 kg 
•  HDL cholesterol level <35 mg/dl and/or a triglyceride level >250 
mg/dl  
• Obesity (BMI >25 kg/m2)  
• Polycystic ovary syndrome 
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•  Race/ethnicity 
• Habitual physical inactivity 
• Family history of diabetes.  
• Previously identified IFG or IGT  
Obesity and Type 2 Diabetes Mellitus: 
•  Free fatty acids and other fat cell products will be more in obese 
patients due to raised adipocyte mass. 
• Insulin resistance in skeletal muscle and liver is due to overproduction 
of free fatty acids and adipokines. 
• Free fatty acid impairs glucose utilization in peripheral tissues like 
skeletal muscles, promote glucose production by the liver, and impair 
beta cell function. 
• Adipocytes secrete a number of biologic products (Adiponectin, RB-4, 
TNF-α, and Leptin). Adipokines regulate insulin sensitivity, body 
weight, and appetite.  
• Insulin-sensitizing adiponectin, is decreased in obesity and this may 
causes hepatic insulin resistance.  
• IL-6 and C-RP levels will be elevated due to adipocyte products and 
adipokines. They are inflammatory markers. 
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Genetic considerations in Type 2 DM: 
• Environmental factors and genetic are the causes of insulin resistance 
and the beta cell dysfunction. 
•  Risk of development of diabetes is more in a person with diabetic 
parents; the risk is around 40% when both parents are affected. 
• The disease is polygenic and multifactorial, environmental factors like 
obesity, smoking can modify the phenotype of an individual.  
• The mechanisms of genetic alterations causing type 2 DM is not clear 
Metabolic alterations in Diabetes Mellitus: 
A) Glucose metabolism: 
           Increased hepatic output and decreased glucose utilization 
 Peripheral uptake- Reduced uptake of glucose in skeletal muscle, cardiac    
muscle and adipose tissue (GLUT- 4 receptors are insulin dependent) 
Glycolysis: 
  Reduced rate of phosphorylation in liver cells (Glucokinase is insulin 
dependent) 
 Glycolytic enzymes are covalently modified by glucagon mediated c 
AMP cascade. 
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 Reduced  availability of Fr 2,6 bisphosphate, reduced activity of PFK-1 
 Reduced rate of glycolysis 
Gluconeogenesis- Increased rate of gluconeogenesis due to - 
 Increased availability of substrates  
                Increased activity and concentration of enzymes of pathway of 
gluconeogenesis under the effect of glucagon 
Glycogen Metabolism- Enzyme activities are altered by glucagon triggered   
phosphorylation cascade. 
 Glycogenesis- Inhibited due to reduced activity of glycogen synthase 
(Phosphorylated form is inactive form) 
 Glycogenolysis- Stimulated due to increased activity of phosphorylase 
(Phosphorylated form is active form) 
 
 TCA cycle- suppressed due to non-availability of oxaloacetate as it is 
channeled towards glucose production 
 HMP Pathway- Suppressed due to reduced activity of glucose-6-P 
dehydrogenase enzyme as that is under the influence of insulin. 
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 Net effect- Elevated plasma glucose levels are due to raise in liver 
glucose production and increased insulin resistance. 
 
Implications of altered carbohydrate metabolism: 
 Hyperglycemia is a net effect of altered carbohydrate metabolism 
 Glycosuria occurs once the glucose level crosses beyond the renal 
threshold 
 Because of osmotic property of glucose, excess loss of water and 
electrolytes through kidney is termed as polyuria. 
  Excess loss of water causes activation of the thirst mechanism 
(polydipsia).  
 Increase in appetite and food intake (polyphagia) is due to negative 
caloric balance which results from tissue catabolism and glycosuria. 
Metabolism of Lipids in Diabetes Mellitus: 
 A) Adipolysis: 
  Triglycerides are mobilized rapidly from adipose tissue leading to raise 
in the levels of plasma FFA.  
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  Numerous tissues take up FFA including liver (except brain) and are 
metabolized to provide energy.  As a result fatty acid oxidation will be 
increased. 
Biochemical Basis of fatty acid oxidation: 
  Normally, in the presence of insulin, the malonyl – CoA levels are high  
 In the presence of high levels of malonyl-CoA, carnitine palmitoyl 
Transferase I levels will be low, so the transportation of fatty acyl-Co 
A’s into the mitochondria will be reduced. 
  Transport of fatty acyl-Co A's into the mitochondria will be increased 
in diabetic patient’s due to low insulin state   
  In mitochondria, FFA are get oxidized and producing acetyl-CoA 
which will be oxidized further in the TCA cycle.  
 
Implication of high rate of fatty acid oxidation: 
 1) Ketosis 
o In the liver cells, large amount of acetyl-CoA is metabolized into the 
ketone bodies. e.g.; β-hydroxybutyrate Acetoacetate and Acetone, 
o  Brain, Heart and Skeletal muscle utilize these ketone bodies for energy 
production 
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o  There will be high levels of FFA and ketone bodies in DM, which will 
reduce the utilization of blood glucose and causes hyperglycemia.  
o  Ketoacidosis develops once the ketone bodies production exceeds 
utilization. 
o  Acetoacetate is get converted into acetate spontaneously and they are 
volatized by lungs producing odor. This is recognized by smell of 
breath. 
Implication of high rate of fatty acid oxidation: 
Hypercholesterolemia: 
                                Excess Acetyl co A, the final product of FFA oxidation 
can enter the pathway of Cholesterol biosynthesis causing 
hypercholesterolemia, increasing the risk for atherosclerosis.  
Serum Triglyceride levels:  
o Lipoprotein lipase (LPL), an enzyme which is present on the surface of 
the, endothelial cells .Main action is to Cleave  TGL 
o  LPL stores the free fatty acids in the adipocytes from circulation. 
o  LPL needs insulin for their action. So in the absence of insulin 
,hypertriglyceridemia occurs 
Net effect- Dyslipidemia (Atherogenic profile): 
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Increased level of circulating free fatty acids 
Ketoacidosis 
VLDL c and LDLC High  
HDLc low (Inverse relation with triglycerides)  
Hypertriglyceridemia 
Hypercholesterolemia. 
Protein metabolism in Diabetes Mellitus: 
• Insulin increases the rate of protein synthesis and reduces the rate of 
protein degradation in our body. 
•  Insulin deficiency leads to increase in the protein catabolism. 
Protein metabolism in Diabetes Mellitus (Net effect): 
         Increased catabolism of protein leads to elevated concentrations of 
amino acids.  
•  Hepatic and renal gluconeogenesis will be increased due to elevated 
concentration of amino acid precursors. 
•  This increased Hepatic gluconeogenesis causes further increase in the 
glucose production  in type 1 DM 
Advanced Glycosylation End Products: 
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                                   Advanced glycosylation end products (AGEs) are the 
products which are produced from non-enzymatic glycosylation of extra 
cellular and intra cellular proteins.  
o Interaction of excess glucose with amino groups on proteins causes non 
enzymatic glycosylation. 
o They are cross-linked proteins (e.g., collagen), accelerate the rate of 
atherosclerosis, deteriorate renal function, decreases the synthesis of 
nitric oxide, induce endothelial dysfunction, and alter the structure and 
composition of extracellular matrix.  
o  AGEs levels correlates with the level of glycaemia, and these products 
tend to increase when renal functions declines. 
Glycated hemoglobin: 
               Glucose and all the other sugar components with the free amino acid 
groups on the alpha and beta chains of hemoglobin is glycated by ketamine 
reactions due to hyperglycemia. 
• These charge separated hemoglobin are collectively referred to as 
hemoglobin A1 (HbA1).  
• The major form of HbA1 is hemoglobin A1C (HbA1c) where glucose is 
the carbohydrate. HbA1c have 4–6% of total Hb A1.  
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• Other forms are glucose-6-phosphate (HbA1a2),fructose-1,6 
bisphosphate (HbA1a1); 
•  chronic hyperglycemia causes abnormal elevation of hemoglobin A1C 
fraction in diabetic persons   
• This test used to assess the glycemic control of an individual for the 
period of 2- 3 months. 
• Glycated hemoglobin’s are detected by following methods like gel 
electrophoresis and high pressure liquid chromatography 
• Hemolytic anemia and hemoglobinopathies and uremia may interfere 
the estimation of Glycated hemoglobin.  
• Glycated albumin levels are also used to assess the control blood sugar. 
they have limited value, because of shorter half-life (20-25 days) 
Normal Hba1c level              ---6-8% 
Fair glycemic control             ---8-10% 
Poor glycemic control             ---10-12% 
Very poor                                 --- >12 
Normal fructosamine level     ---0.5-1.5 ng/dl 
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  PATHOGENESIS OF COMPLICATIONS OF DIABETES 
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      Metabolic syndrome definition 
 
                    International diabetes federation definition 
 
 
Central obesity (defined as waist circumference > 94cm for europid men 
and > 80cm for Europid women, with ethnicity specific values for other 
groups) 
 
Plus any two of the following four factors: 
 
 Raised TG level: 150 mg/dl, or with specific treatment. 
 
 
 Reduced HDL cholesterol: <40 mg/dl  in males and < 50 mg/dl in 
females, or with specific treatment  
 
 
 Raised blood pressure: systolic BP>130mm/Hg or diastolic BP > 85 
mm Hg, or  normal Bp with specific treatment 
 
 
 Raised fasting plasma glucose (FPG) > 100 MG/dl, or previously 
diagnosed type 2 diabetes 
 
 
 
  
 
[44] 
 
 
Targets for treatment of the components of metabolic syndrome 
                                                                    High risk              very low risk* 
 
Blood pressure(mm/hg)                            <135/85                   <120/80 
 
Fasting glucose (mmol l-1)                          <6.1 (110mg/dl)     <5.6 (100mg/dl) 
 
2-h post-challenge plasma                         <10 (180 mg/dl)        <8 (144 mg/dl) 
Glucose (mmol l-1) 
 
Triglycerides (mmol l-1)                           <1.7 (<150mg/dl)     <1.5 
(<132mg/dl) 
 
High – density lipoprotein                        <0.9 / >1.0                    >1.0 / >1.1 
 
Cholesterol (mmol l-1)                               (35/39 mg/dl)               (39/43 mg/dl) 
 
 
*Confirmed Atherosclerosis Vascular Disease 
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Medical nutrition therapy: 
1) Diet planning 
2) Exercise 
                        Medical nutrition therapy is a component of preventing type 2 
DM in individuals with IGT and for achieving glycemic control, weight 
reduction 
RECOMMENDED DIETARY COMPOSITION FOR PATIENTS WITH 
DM: 
Diet Energy intake % 
Carbohydrates  
Sucrose 
Proteins 
Fat 
n-6 PUFA 
n-3 PUFA 
MUFA 
saturated fat 
45-65 
Up to 10 
10 -15 
<30 
<10 
Consume oily fish once/ twice a week  
10 – 20  
<10 
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Benefits of physical activity: 
1) Improving Insulin sensitivity 
2) Weight management  
3) Improving bone density 
4) Mental well being 
5) Improving lipid profile 
6) Improving blood pressure control 
7) Improving cardio vascular function. 
 
  ORAL HYPOGLYCAEMIC : 
                     The use of oral medications with diet & exercise can 
manage the problem but oral hypoglycaemics are not insulin & 
therefore cannot replace insulin. 
  Oral hypoglycemics help the body to utilise or make insulin. 
– Beta cells must make enough insulin to work, otherwise 
combination with insulin is necessary. 
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Classes of Oral Hypoglycaemic Agents: 
Target insulin secretion: 
– Sulphonylureas (glibenclamide) 
– Meglitinides (repaglinide) 
Target insulin resistance: 
– Biguanide (metformin) 
– Thiazolidinedione’s  (rosiglitazone) 
 Target glucose absorption from intestine: 
– Alpha glucosidase inhibitors (acarbase) 
Biguanide: Metformin 
 Decreases hepatic glucose output 
 Increases peripheral uptake of glucose into cells  
 Monotherapy or adjunct 
 Does not produce weight gain, useful in obese patients. 
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 Dose:  
– 500mg od increasing gradually to 500mg tds 
– Max dose 3gm per day – but most of the patients tolerate 2gm. 
                    Reduces HbA1C by 1-2% 
 Contraindications: 
– May provoke lactic acidosis  
– Contraindicated with Renal impairment 
– Liver & heart failure and in Severe dehydration 
 Side effects: 
– Nausea, vomiting, diarrhoea, abdominal discomfort, impaired B12 
absorption 
Sulphonylureas: 
             Stimulate beta cells to release insulin from functioning pancreatic 
cells 
Examples: 
             Glibenclamide (Daonil, Glimel) 
– Widely used, long acting  
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– Avoid in elderly, Renal impairment  
 Gliclazide (Diamicron, Nidem) 
 Glipizide (Minidiab, Melizide) 
 Glimepiride (Amaryl, Dimirel) 
 Dose: varies per drug  
 Drug interactions: multiple 
 Reduces HbA1C by 1-1.5%  
 No lag in response.Drug of choice in lean patients. Drugs are broken 
down in liver so avoided in people with liver and renal impairment 
 Adverse Effects: 
 GI disturbances, headache; bone marrow depression 
 Mild skin reactions, photosensitivity, mild alcohol intolerance. 
 Hypoglycaemia 
 Weight gain 
 5-10% secondary failure rate / year 
 Long Term Side Effects are exhaustion of Beta cells. Secondary failure 
of treatment is high Therefore, use Short-acting versions at lowest 
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effective doses. Secondary failure is inevitable ,after many years of 
treatment  
  
Alpha Glucosidase Inhibitors 
                                   Reduces glucose absorption from the gut by inhibiting 
the breakdown of disaccharides to monosaccharaides such as glucose. 
 Only effective if taken at same time as food, as drug needs to reach 
intestines at same time as food to work. 
 Example: 
 Acarbose (Glucobay) 
 Monotherapy or adjunct 
  
Dose: 
 50mg OD increasing gradually to TDS, dose can be increased up to 
200mg TDS. Take with or just prior to meal 
  
 Side effects: 
 flatulence, diarrhoea, abdominal distension & pain 
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 Contraindications 
 Pregnancy / breast-feeding  
 Liver and severe renal impairment 
 Inflammatory bowel disease & intestinal obstruction 
 In therapy: 
 Add-on to treatment with metformin or sulphonylureas  
 Part of triple therapy  
 Monotherapy  
 With insulin in Type 1 diabetes 
– Reduces HbA1C by 0.5%. relatively Safe.it has weight neutral 
property 
– Dose coupled with meals 
– Monitor LFT during 1st 6-12mths 
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Meglitinides: 
 Prandial Glucose Regulators (PGR’s) 
 Stimulate beta cells to release insulin, response however is glucose 
dependent 
 Following meals there is an early phase insulin release 
 In Type 2 diabetes, this is lost causing post prandial spikes 
 PGR mimic release of physiological insulin, as they are short acting and 
do not stimulate the beta cells constantly 
 Repaglinide (NovoNorm) 
 Dose: initially 500mcg, up to 4mg as a single dose 
 Tablets should be taken 30 mins before a main meal 
 Contraindications: 
 Diabetic ketoacidosis 
 Pregnancy & breast feeding 
 Type 1 diabetes 
 Severe hepatic impairment (repaglinide only) 
    Monitoring:  LFT   periodically  
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 Repaglinide: 500mcg, dose can be  modified  according to response 
every 1-2weeks;  dose can be increased up to 4mg as a single dose, max 
16mg daily. 
 Nateglinide: initially 60mg tds, adjusted according to response up to 
max 180mg tds 
 Quickly lowers post prandial glucose levels (no lag before response) 
 HbA1C 0.5-2% .it has short half-life. Meal time flexibility 
 Risk of weight gain 
  
Thiazolidinediones:     
                                           Improves insulin sensitivity skeletal muscle,  
adipose tissue & liver, thereby promoting uptake of fatty acids & glucose at 
these sites .Counteract insulin resistance .Reduces HbA1C by 1-2%.Beneficial 
effect on lipids 
         
Examples: 
       Pioglitazone(Actos), Rosiglitazone (Avandia) 
       Adjunct with either  SU or metformin 
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 Dose: varies per drug 
        Pioglitazone (Actos): 15-30mg once daily 
        Rosiglitazone (Avandia): 4 mg/day, or + metformin 8 mg/day 
Contraindications: 
 Pregnancy / breast-feeding 
 Liver impairment  
 Heart failure 
Side-effects: 
                     Dizziness 
 Oedema,  
 Headache,  
 Weight gain. 
 
Optimal Glycemic Control: 
 -One of the primary goals in treating diabetes is to ‘treat to target’ in 
terms of HbA1C 
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 -With long term treatment, 75% of patients do not maintain optimal 
glycemic control (<7% HbA1c) with monotherapy alone1 
 -Optimal combinations of oral therapy to treat diabetes need to be found 
to achieve this target 
 -Combination therapy used when monotherapy fails  
 Insulin therapy, or  
 Insulin therapy + metformin, or 
 Insulin therapy + sulphonylurea  
 Monitor glycaemic control : 
 Target  HbA1C = 7% 
 Many oral treatment options 
 Change therapy in response to poor control  
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                     Insulin 
 
Metabolic benefits of insulin therapy 
 
 Reduces fasting and postprandial glucose levels 
 Suppresses hepatic glucose production 
 Stimulates peripheral glucose utilization 
 Increases glucose oxidation/storage in skeletal muscles 
 Improves abnormal lipoprotein composition 
 Reduces glucotoxicity 
 Improves endogenous secretory ability 
 Reduces glycosylated end products 
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Anti-catabolic effects of insulin (inhibits) 
Liver                                    muscle                                         adipose tissue 
Glycogenolysis                        proteolysis                                      lipolysis 
Gluconeogenesis                     amino acid output                              
Fatty acid oxidation 
Ketogenesis 
Proteolysis 
 
 
Anabolic effects of insulin (promotes) 
     Liver                                      muscle                                         adipose tissue 
Synthesis                                uptake                                                    uptake 
Glucagon                                 glucose                                                 glucose 
RNA                                        amino acids                                          protein 
Amino acids 
Fatty acids                               synthesis                                              synthesis 
Triglycerides                           glycogen                                              glycerol 
Protein                                    fatty acids    
triglycerides 
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Types of Insulin: 
Source: 
– Animal sources  
– Recombinant DNA = human insulin 
Duration of action: 
– Rapid acting  
– Short acting  
– Intermediate acting  
– Long-acting  
– Biphasic 
Rapid-acting Insulin: 
 Rapid acting = analogue insulin 
 Examples 
– Humalog (Lilly)  
– Novorapid (Novo Nordisk) 
 Very rapid onset approx 15 mins;  
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– ensure food intake after administration 
 Peak action 1 hour, duration of action 4 hours 
 Can be administered just before or even after meals  
 Hypoglycaemic effect over in < 3 hours  
 Clear solution 
 Only form that can be given IV 
  May be combined with longer acting insulin 
Short-acting Insulin: 
 Short acting = neutral or soluble insulin 
 Rapid onset of action (30-60 mins) 
 ensure food intake ½ hour after administration 
 Peak 2-4 hours, duration 6-8 hours 
 Examples 
 Human Actrapid (Novo Nordisk) 
 Humulin R (Lilly) 
 Hypurin Neutral (Beef) (Aspen) 
 Injected < 30 mins before meals 
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 Clear solution 
Intermediate-acting Insulin: 
 Intermediate acting = isophane insulin (NPH) 
 Cloudy due to the addition of a protein  
–  (isophane or zinc) 
 Must be mixed well before use  
 Examples: 
– Humalin NPH  
– Hypurin Isophane 
– Protophane  
– Levemir – Detemir,  
 Retarded onset = 1–2 hrsPeak 4-12 hours 
 Prolonged duration of action lasting 8-20 hrs  
 Always draw up clear before cloudy if 2 types of insulin are required  
 
Long-acting Insulin: 
 Lantus –Glargine Insulun- Once daily  
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 Duration of action 24 hrs; Peakless (Clear) 
Biphasic Insulin: 
 Mixture of soluble or analogue insulin  and isophane 
 Offer double insulin release profiles from single injection form. 
 Examples: 
– Humalog Mix 25 or Mix 50 (Lilly) 
– Human Mixtard 10/20/30/40/50 (Novo Nordisk) 
– Novomix 30 (Novo Nordisk) 
Insulin Regimens: 
 Variety of insulin regimens  
– Tailored to meet the needs of different people with diabetes  
 Treatment option chosen reflects 
– Type of diabetes 
– Person’s lifestyle, age and ability to self-test blood glucose 
– Presence of obesity  
– Choice 
 Goal is insulin release profile most similar to physiological state. 
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Once-Daily: 
 long-acting basal or intermediate acting insulin 
 insulin should be given at breakfast 
 Simplest regimen  
 Sufficient for many elderly Type 2 people 
 Often used in combination with OHA  
 Obese Type 2 person uncontrolled on maximal doses of oral therapies  
– Example: Metformin + once daily insulin 
Twice-Daily: 
 Twice-daily biphasic insulin 
 Very popular regimen  
 Often used in treatment of Type 2 diabetes 
 Administered in morning and at teatime  
 Can be quite restrictive as meal times cannot be varied 
Basal-Bolus: 
 Four daily injections  
– Before meals (bolus) 
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                    3 short- or rapid-acting insulin doses 
– Bedtime (basal) 
                      Once-daily intermediate-acting insulin 
– Can adjust bolus injections for eating patterns  
 Three Times Daily: 
– Mixture of short- and intermediate-acting insulin before breakfast 
or 
– Mixture of short-acting insulin before the evening meal or 
– Intermediate-acting insulin at bedtime  
 Regimen often adjusted depending on the person’s circumstances 
 Flexibility offered to the prescriber 
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Approximate time – course of action of various insulin preparations 
Kind of insulin                onset of                     peak of                           total 
Preparation                      action                       activity                        duration 
                                            (hr)                            (hr)                     of action 
(hr) 
SHORT ACTING* 
Regular                                 0.5-l                       2-4                                 4-6 
Semilente                             1-2                          3-6                                8-12 
INTERMEDIATE ACTING* 
NPH                                      3-4                       10-16                              20-24 
Lente                                     3-4                       10-16                              20-24 
LONG ACTING* 
PZL                                      6-8                        14-20                                 32 
Ultralente                             6-8                        14-20                                 32 
BIPHASIC** 
PREMIXED (NPH + REG)  0.5                      2-10                                12-18 
ANALOGUES 
SHORT ACTING             within a few                 1                                  4 
Lispro (Humalog)                  minutes 
Aspart (Novolog) 
Glulisine (Apidra) 
LONG ACTING 
Glargine (Lantus)                   
Detemir (Levemir)            -------------Peak less action for 24 hrs--------------- 
PREMIXED 
Novomix 30/70 
Humalog mix (25:75 & 50:50) 
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          DURATION OF ACTION OF VARIOUS INSULINS 
 
 
Factors affecting the disposal of injected insulin 
Injection site 
a. Anatomic site 
b. Exercise 
c. Depth 
d. Insulin concentration 
e. Mixing insulin preparations 
f. Local tissue degradation 
g. Intra – subject coefficient variation 
Plasma 
a. Antibody binding and release of insulin 
b. Physical state of modified insulin in serum 
Insulin receptors 
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a. Final disposal of insulin by liver, and kidney cell – surface receptors 
 
 
Adverse Effects of insulin: 
 Hypoglycemia 
 Allergic reactions,  
– usually local site & usually diminish 
– less likely with human insulin 
 Insulin lipodystrophy 
– Atrophy or hypertrophy of subcutaneous fat at injection sites 
– Rotate within sites to prevent 
 Insulin insensitivity or resistance 
– Requires higher doses of insulin 
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                                          Hypoglycemia 
ADA definition of hypoglycemia: 
                  AMERICAN DIABEDES ASSOCIATION group on 
hypoglycemia in diabetes as “all episodes of abnormally low plasma sugar 
concentration that expose the individual to potential harm”. 
Clinical classification: 
1) Severe hypoglycemia 
2) Documental symptomatic hypoglycemia 
3) Asymptomatic hypoglycemia 
4) Probable symptomatic hypoglycemia 
5) Relative hypoglycemia 
 
1) severe hypoglycemia: 
              Those who need active medical intervention like administration of 
carbohydrate glucagon for the hypoglycemia episodes is known as severe 
hypoglycemia 
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2) Documental symptomatic hypoglycemia: 
                Patients developing symptoms of hypoglycemia in the plasma 
glucose concentration of ≤70 is known as documented symptomatic 
hypoglycemia 
3) Asymptomatic hypoglycemia: 
               Patients with atypical symptoms of hypoglycemia with plasma sugar 
concentration of ≤ 70 mg/dl is known as asymptomatic hypoglycemia 
4) Probable symptomatic hypoglycemia: 
               Patients with typical symptoms of hypoglycemia plasma glucose 
concentration of ≤ 70mg/dl is known as probable symptomatic hypoglycemia. 
5) Relative hypoglycemia: 
               Diabetic patients with typical symptoms of hypoglycemia with 
plasma glucose concentration of ≤ 70 mg/dl is known as relative 
hypoglycemia 
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Classification of Hypoglycemia 
 
1. REACTIVE HYPOGLYEMIA (Post prandial Hypoglycemia) 
 
a. Post – gastrectomy 
b. Early stage of maturity onset  diabetes 
c. Inborn errors off metabolism (e.g. Hereditary Fructose 
intolerance & galactosemia 
d. Idiopathic post prandial syndrome 
 
2. FASTING HYPOGLYCEMIA 
 
A. DEFICIENT GLUCOSE PRODUCTION (NORMAL INSULIN 
LEVEL) 
 
1. Hepatic Dysfunction 
 
a. Glycogen storage disease 
b. Advanced stage of storage disease 
c. Hepatoma 
 
2. Endocrine dysfunction 
a. Addison disease 
b. Hypopituitarism 
c. Glucagon deficiency 
 
3. Sepsis 
a. Cytokines associated to endotoxinemia increase insulin release. 
 
B. OVER UTILIZATION OF GLUCOSE (ELEVATED INSULIN 
LEVELS) 
 
1. Hyperinsulinemia 
 
a. Insulinoma 
b. Nesidioblastosis 
c. Auto antibodies against insulin or insulin receptor 
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2. Inappropriate insulin level: 
a. The extra pancreatic tumors 
b. Cachexia with fat depletion 
c. Systemic carnitine deficiency 
 
C. SUBSTRATE DEFICIENCY 
a. Chronic starvation 
b. Chronic renal failure 
c. Ketotic hypoglycemia of infancy 
 
D. COMPROMISED GLUCOSE COUNTER REGULATION 
 
1. Fixed syndrome 
a. Defective glucose counter regulation 
b. Hypoglycemic unawareness 
 
2. Dynamic syndrome: Elevated blood glucose thresholds resulting 
from 
a. Effective intensive insulin therapy 
b. Recent antecedent hypoglycemia 
c. Therapy with a adrenergic antagonist 
 
3. Drug induced hypoglycemia 
a. Exogenous insulin (iatrogenic, fictitious) 
b. Sulfonylurea 
c. Miscellaneous – Salicylates, Propranolol, Tranquilizer 
d. Toxins - Pentamide, Quinine etc.  
 
  
 
Pathophysiology: 
- Human brain consumes 5 gms glucose per hour  
- Blood supply to brain is around 1 L/mt. 
- It can reserve around 1.5 gms of glycogen as reserve 
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- When blood sugar level falls below 45 mg/dl, the hypothalamic 
center get activated and sending signals to following centers  
 
1) Hunger Center 
 
2) Bulbar reticular system leading onto activation of 
sympathetic and parasympathetic system. 
 
3) Pituitary leading on to release of ACTH, GH. 
 
                 These changes causes gluconeogenesis and raise in blood sugar 
level. 
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SIGNS AND SYMPTOMS OF HYPOGLYCEMIA 
 
Clinical Signs and Symptoms of Hypoglycemia 
Sympathetic / parasympathetic 
Activation 
Neuroglycopenia 
 
Clinical signs and symptoms of 
Adrenergic activation  
                     
  Pallor, tremor, palpitations of    
anxiety  
 
Acute sensation of hunger 
 
Occasionally hypothermia, 
vomiting, fever, moderate 
tachycardia, crisis of systolic 
hypertension 
 
a. Clinical signs and symptoms of 
parasympathetic activation  
 
Nausea and eructation  
 
Cold sweating 
 
Mitigation of expected     tachycardia 
or true bradycardia 
 
Mild hypotension 
 
 
 
 
Clinical signs and symptoms of 
neuroglycopenia 
 
Headache, dizziness, fatigue, 
 irritability or apathy and lethargy 
 
Frequency yawning and perioral  
  numbness 
 
Disturbed vision and diplopia 
 
Paresthesia and motor dysfunction 
 
Cognitive impairment, mental 
confusion  
  and inebriation 
 
Personality changes, psychotic 
  behavior  
 
Occasionally transient hemiparesis or 
focal neurologic deficits 
 
Convulsions ( in children simulating 
true crisis of epilepsy) 
 
Semi – coma, coma and even death 
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PREDISPOSING FACTORS IN DRUG INDUCED DIABETIC 
HYPOGLYCEMIA: 
 
Predisposing factors in drug – induced diabetic hypoglycemia 
 
Under nutrition or omission of food 
or  Starvation 
 
 
Unexpected exercise Renal or 
Hepatic dysfunction    
                                         
Abuse  of alcohol 
 
 
Acute sickness 
 
 
Erroneous high insulin or 
sulfonylurea  doses 
 
 
Increased absorption of insulin 
from the site of injection 
 
    
 
Administration of a β-blocker 
Defective counter regulation, 
hypoglycemia unawareness 
 
 
 
 
 
Lowered glycemic threshold for 
hypoglycemia and counter regulation 
during intensive insulin treatment 
(with compromised recognition of 
developing hypoglycemia) 
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Hypoglycemic unawareness: 
 
                       Failure of an individual to develop autonomic symptoms of 
sweating, tremor, hunger. 
  
              These symptoms usually absent in 20 – 50% of long standing type 1 
DM 
Classical features:   
- One episode of hypoglycemia confers increased risk of 
subsequent episodes of hypoglycemia 
- Recent episode of hypoglycemia reduces the sympathetic  
response to subsequent hypoglycemia 
- Beta blocker should be used cautiously in DM patients. because 
they will increase blood glucose threshold for symptoms of 
hypoglycemia by blocking adrenalin action 
Diagnosis: 
                Diagnosis mainly based on “whipple’s triad” 
1) Low plasma glucose concentration 
2) Symptoms of hypoglycemia 
3) These symptoms relived by correction of blood sugar level 
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       Sequence of Events in the development of Hypoglycemia – associated 
Autonomic Failure 
 
 
Type 1 DM 
Insulin deficiency On Insulin  
              Decreased 
Glucagon response 
Strict glycemic status Recurrent severe 
hypoglycemia 
Counter regulatory 
hormone deficiency 
Hypoglycemia 
unawareness 
Decreased 
symptom response 
Central (CNS) automatic failure 
Decreased adrenaline 
response 
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                               Hypoglycemic variants 
1) Somogyi phenomenon 
2) dawn phenomenon 
Somogyi: 
                   Post Hypoglycemic Hyperglycemia. 
                    Hypoglycemia induced hyperglycemia due to increased secretion 
of counter regulatory hormones.  
                                  If the insulin dose is increased beyond the amount 
required for any given portion of a day, there is a counter regulatory hormone 
response, resulting in hyperglycemia. Reduction of insulin dose is advised in 
such a situation  
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 Dawn phenomenon: 
  Dawn    => high fasting blood sugar. 
                      Many patients with type 1 DM demonstrates early morning 4 – 8 
A.M hyperglycemia that is aggravated again by intake of food during break on 
fast.  
                        This could be due to peripheral utilization or increased hepatic 
glucose production or both. In this condition excess of insulin is needed to 
control hyperglycemia. Early morning blood sampling at 3 A.M is necessary 
to differentiate both these conditions. 
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STEP CARE TREATMENT FOR HYPOGLYCEMIA 
Oral glucose (or) sugar (or) fruit juice 
                                                  
                                       Glucagon (or) Adrenaline 
 
                                               25% or 50% glucose  
                                        Forced Diuresis (only for OHA) 
                                                                                                10%      
                                                                                              Dextrose 
                                                  Hydrocortisone                   infusion to 
                                                                                                    be 
                                                                                              continued 
                                                  iv Mannitol 
 
                                                          + 
                                                  Dexamethasone 
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MECHANISM LINKING DIABETES AND CARDIOVASCULAR 
DISEASE: 
1) Adipokines: 
           These are produced from adipose tissue  
Adipokine Actions 
 
Adiponectin 
 
 
 
 
 
 
 
 
Leptin 
 
 
 
angiotensinogen 
and angiotensin II 
 
 
 
 
 
 
Tumor necrosis 
factor(TNF) 
 
Plasminogen 
activator inhibitor-
1 (PAI-1)  
 
Anti – inflammatory and anti atherogenic properties 
Low levels characteristic of persons at increased risk of  
diabetes 
Decreases uptake of oxidized LDL 
Decreases monocyte adhesion to endothelial cells 
Decreases expression of adhesion molecules  
Decreases proliferation and migration of vascular 
smooth 
Muscle cells 
 
Regulates energy intake and expenditure 
Enhances cellular immune responses  
Increases blood pressure levels 
 
Vasoconstrictive 
Enhances the formation of foam cells 
Stimulates intracellular adhesion molecule-1,vascular 
cell adhesion molecule-1, MCP-1, M-CSF expression in 
the cells of the vessel wall increases monocyte-
macrophage platelet activity in the vessel wall  
Endothelial dysfunction 
 
Expression of adhesion molecules on the surface of the 
endothelial cells and VSMCs  
 
Inhibits the breakdown of fibrin clots promotes 
thrombus formation 
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2) Endothelial dysfunction: 
                      The normal endothelium maintains the normal vasomotor tone 
and balancing coagulation cascade. 
 
- Stimulation of insulin receptors activates P1 R-3, there by 
producing nitric oxide, leading on to vasodilation, which also 
having anti-inflammatory, antithrombotic and atherogenic 
properties.                                   
 
- In diabetics during hypoglycemic episodes, endothelial cells 
secretes endothelin – I, that produces vasoconstriction, 
increasing  vascular permeability, VSMC proliferation 
VSMC migration and proliferation: 
                    Insulin resistance initiates pro atherogenic cellular 
events - proliferation and migration of smooth muscles 
Monocyte/ macrophage adhesion and migration: 
                     Insulin receptor found in monocyte /macrophage 
molecules. So insulin resistance increase macrophage apoptosis. 
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 There by accelerating the development of vascular lesion and 
contribute to plaque rupture. 
 
Insulin resistance: 
      - Insulin resistance syndrome: 
                  1)  Hypertension 
                  2)  Dyslipidemia 
                  3)  Hyper coagulable state 
     - Insulin resistance increases the atherosclerotic plaque 
formation.  So it is an independent risk factor for atherosclerosis. 
Usually insulin resistance precedes; 10-15 years after the 
development of type 2DM. Insulin resistance can be measured by 
HOMEOSTASIS MODEL ASSESSMENT METHOD  
               
               HOMA – IR = sr.Insulin * sr. Glucose /22.51    
- One unit increase in HOMA - IR - 5.4 % increases risk for 
cardiovascular disease. 
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                                        Q-T INTERVAL 
QT interval=> duration of ventricular electrical systole 
- Measured from beginning of QRS complex to end of ‘T’ wave. 
- Because of  practical difficulties in measuring Q-T interval, 
American heart association electrocardiography and arrhythmia 
committee recommends global measurements of intervals, 
including QT from all 12 leads 
  QT interval in precordial leads depends on: 
1)  Proximity of leads with heart. 
2) Local repolarization duration at the site of facing the recording 
electrode. 
                   
      QT dispersion => difference between the shortest * longest QT interval 
among standard leads 
      QT interval decreases with increasing heart rate, Bazett’s formula used to 
calculate corrected QT 
                                         QT = QT/√RR 
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                Normal QT interval in male – 0.397 s 
                                                  Female - 0.415 s 
               Normal corrected QT interval M = 0.440 s 
                                                                F = 0.460 s 
               Main problem in bazett’s formula is that will overcorrect at rapid 
heart rate.  So they introduced other formulas.  But none of them are 
significant. 
              Framingham study was conducted in 5000 adults aged 28-62 yrs. for 
calculating QT interval.  Which is superior to bazett’s & other formula 
Q-T interval variation: 
- Q-T interval is more in the evening & at night  
- Sleep prolongs the Q-T interval by 18msec at heart rate 60 and 
by 21ms at a heart rate of 50 beats/mt. This is due to autonomic 
tone 
Causes of QTc interval prolongation: 
- During sleep 
- Hypothermia 
- Acute MI 
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- Hypocalcaemia 
- acute myocarditis 
- procainamide effect 
- quinidine  effect 
- cerebral injury 
- HOCM 
- Pulmonary embolism 
- Increased ICT 
- MVP 
- Hypothyroidism 
- Complete block with torsade pointe 
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                            MATERIALS AND METHODS 
DESIGN OF STUDY: 
                         Observational study. 
PERIOD OF STUDY: 
                          10 months (JANUARY2014 TO OCTOBER2014) 
SELECTION OF STUDY SUBJECTS: 
                             This study is to be conducted in diabetic patients who are 
all admitted in medical ward with symptoms of severe hypoglycemia at Govt. 
Rajaji Hospital, Madurai. Severe hypoglycaemia was defined in this study, as the 
condition requiring active medical intervention such as carbohydrate 
administration when plasma sugar level was <60 mg/dl. 
 
 STUDY POPULATION: 
                                       100 cases 
 
ETHICAL CLEARANCE:  
CONSENT: Individual written and informed consent. 
ANALYSIS: STATISTICAL ANALYSIS. 
CONFLICT OF INTEREST: NIL 
FINANCIAL SUPPORT:  NIL 
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INCLUSION CRITERIA: 
• Type 2 DM & Type1(in all age groups) 
EXCLUSION CRITERIA: 
• Patients with electrolyte abnormalities. 
• Coronary artery disease. 
• Concurrent use of drugs which causing Q-T prolongation (quinidine, 
procainamide, Tri & Tetra cyclic antidepressant). 
ANTICIPATED OUTCOME: 
 Prolongation of corrected Q-T interval during the episodes of 
hypoglycemia (Normal QTc M=440ms, F=460ms) 
DATA COLLECTION: 
 100 cases were selected for the study after applying the inclusion and 
exclusion criteria as stated above and subjected to following baseline data and 
clinical characteristic line  
                 The baseline characteristics of the patients- age, sex, diabetic (both 
type 1 and type 2) patients with symptoms of hypoglycemia with low glucose 
level , duration of diabetes, Q-T interval were recorded in proforma prepared 
according to need of study. 
     Corrected Q-T interval was calculated by using bazett’s formula  
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LABORATORY INVESTIGATION: 
 RBS  (Venous blood sample for glucose analysis). 
 Sr. Electrolytes and  
          Sr. Calcium     
OTHER INVESTIGATIONS: 
        ECG 
        ECHOCARDIOGRAM 
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                            RESULTS 
AGE DISTRIBUTION IN HYPOGLYCEMIA: 
 
 
Comments: 
                          In our study 48 patients had hypoglycemia in the range of 60-
40 mg/dl, and 52 patients had hypoglycemia below 40 
 
 
 
 
Sugar level(mg/dl) Age in years(18-74yrs ) 
Cat I(60-50) 28 
Cat II(40-49) 20 
Cat III(30-39) 24 
Cat IV(<30) 28 
Total 100 
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AGE DISTRIBUTION IN HYPOGLYCEMIA: 
 
 
Category I   – blood sugar level 60-50mg/dl 
Category II – blood sugar level 40-49mg/dl 
Category III- blood sugar level 30-39 mg/dl 
Category IV- blood sugar level <30 mg/dl 
 
 
 
28 
20 
24 
28 
age in yrs(18-24) 
cat I
cat II
cat III
cat IV
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SEX DISTRIBUTION IN HYPOGLYCEMIA: 
 
Sugar 
mg/dl 
Male (%)  Female 
(%) 
Total 
Cat -I 18(30.50) 10(24.39) 28 
Cat -II 12(20.33) 8(19.51) 20 
Cat -III 14(23.72) 10(24.39) 24 
Cat- IV 15(25.42) 13(31.70) 28 
 
 
Comments: 
                    59 males 41 females had hypoglycemia in our study. So incidence 
of hypoglycemic more in male population in our study.  
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SEX DISTRIBUTION IN HYPOGLYCEMIA: 
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INCIDENCE OF HYPOGLYCEMIA IN TYPE-2 AND TYPE-1 
DIABETES: 
 
 
Comments: 
                  In our study, 38 male and 14 females of type-2 DM Patients are 
had hypoglycemia below 40 mg/dl. 33 males and 15 females of type 1 DM 
patients had hypoglycemia in the range of 60-40 mg/dl. Among diabetes 
males are commonly affected than females. 
 
 
 
Sugar  TYPE – II TYPE – I Total 
Cat- I 18 
25.35% 
10 
34.48% 
28 
Cat -II 15 
21.12% 
5 
17.24% 
20 
Cat -III 18 
25.35% 
6 
20.68% 
24 
Cat- IV 20 
28.16% 
8 
27.58% 
28 
 71 29 100 
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INCIDENCE OF HYPOGLYCEMIA IN TYPE-2 AND TYPE-1 
DIABETES: 
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cat IV
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INCIDENCE OF Q-T PROLONGATION IN VARIOUS CATEGORIES 
OF HYPOGLYCEMIA: 
Sugar Level QT(c) Prolongation Percentage 
    Cat-I  (28) 10 13.33 
     Cat -II (20) 14 18.67 
     Cat -III (24) 23 30.67 
Cat -IV (28) 28 37.33 
Total 75 100 
‘p’ value 0.048    
Significant 
 
Chi square value 3.89  
 
Comments: 
24 patients from Cat-1& 2 and 51 patients from Cat-3&4 are developed Q-T 
prolongation in our study with significant p value of .048.so when 
hypoglycemia is severe, incidence of Q-T prolongation is also increases due to 
repolarization abnormalities.   
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INCIDENCE OF Q-T PROLONGATION IN VARIOUS CATEGORIES 
OF HYPOGLYCEMIA: 
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INCIDENCE OF Q-T PROLONGATION IN DIABETIC PATIENTS: 
 
 
 
 
 
 
 
 
Comments: 
                        In our study 49 patients in type 2 DM, 26 patients in type 1 
DM developed Q-T prolongation. Type 2DM is more common than type 1 
DM in our country. Incidence of  Q-T prolongation are more with insulin 
treatment. 
 
 
 
Sugar 
level 
mg/dl 
Type – I 
Prolongation 
(%) 
Type - II 
Prolongation 
(%) 
Total 
    Cat I 4 
(15.38%) 
6 
(12.24%) 
10 
(13.33%) 
Cat II 5 
(19.23%) 
9 
(18.37%) 
14 
(18.67%) 
    Cat III 7 
(26.92%) 
16 
(32.65%) 
23 
(30.67%) 
 Cat IV 10 
(38.46%) 
18 
(36.73%) 
28 
(37.33%) 
Total  26 49 75 
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INCIDENCE OF Q-T PROLONGATION IN DIABETIC PATIENTS: 
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MEAN Q-T INTERVAL IN VARIOUS CATEGORES: 
 
Sugar mg/dl Mean Q-T interval (ms) 
Cat- I 448.21 
Cat- II 471.65 
Cat-III 505.08 
Cat- IV 519.1 
P VALUE –0.001  
 
Comments: 
                 Q-T interval prolongation is depends on the severity of 
hypoglycemia. In our study 448 ms was a mean Q-T interval in stage 1. As the 
stage advances     Q-T prolongation also increases. Mean Q-T interval of stage 
4 was 519 ms. 
P value-0.001 
  
 
[99] 
 
 
MEAN Q-T INTERVAL IN VARIOUS STAGES: 
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INCIDENCE OF ARRHYTHMIAS IN VARIOUS CATEGORIES OF 
HYPOGLYCEMIA:  
Comments: Hypoglycemia causes repolarization abnormality there by 
increasing the interval of Q-T. This causes arrhythmias and SCD. In our study 
4 patients in Category -III 6 patients in Category- IV developed arrhythmias 
with statistically significant P value of   0.010. Chi square value-6.67 
 
Sugar Level No of patients with Arrhythmias Percentage 
Cat-I  (28) 0  
Cat-II (20) 0  
Cat-III (24) 4 40 
Cat-IV (28) 6 60 
Total 10 100 
‘p’ value 0.010 
Significant 
 
Chi square value 6.67  
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INCIDENCE OF ARRHYTHMIAS IN VARIOUS STAGES OF 
HYPOGLYCEMIA: 
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INCIDENCE OF DEATHS IN VARIOUS CATEGORIES OF 
HYPOGLYCEMIA: 
Sugar Level No of Deaths Percentage% 
Cat-I  (28) 0  
Cat-II (20) 0  
Cat-III (24) 1 16.66 
Cat-IV (28) 5 83.33 
Total 6 100 
‘p’ value 0.047 
 Significant 
 
Comments: 
                              Q-T interval is prolonged in severe in hypoglycemia. This 
prolonged Q-T interval causes arrhythmias and death. In our study 5 patients 
were died due to arrhythmias in Category -IV and 1 patient died in Category- 
III. There were no deaths observed in Category I&II with statistically 
significant P value of 0.047. 
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INCIDENCE OF DEATHS IN VARIOUS CATEGORIES OF 
HYPOGLYCEMIA: 
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INCIDENCE OF Q-T PROLONGATION IN VARIOUS DURATION OF 
DM: 
Duration of Diabetes Number of patients with  
Q-T prolongation 
Percentage 
5 – 10 years  (10) 3 4.00 
11 – 20 years (30) 14 18.67 
21 – 30 years (60) 58 77.33 
Total 75 100 
                                 P VALUE --<0.0001 SIGNIFICAN 
                           CHISQUARE –47.2 
Comments: 
                    Q-T interval increases when the duration of diabetes increases.in 
our study 58 patients have 21-30 years of diabetes.14 patients have 11-20 
years of diabetes. Only 3 patients have 5-10 years of diabetes. 
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INCIDENCE OF Q-T PROLONGATION IN VARIOUS DURATION OF 
DM: 
 
 
 
 
 
 
 
 
 
                                            
3 
14 
58 
Duration of diabetes 5-10 yrs 11-20 yrs 21-30 yrs
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                                  DISCUSSION 
                Hypoglycemia is one the common complication of DM patients 
with insulin therapy.  Hypoglycemia causes QT prolongation, there by 
inducing arrhythmias and sudden cardiac death.  Incidence of hypoglycemia 
induced SCD in Indian population is around 1-2%.  Repolarization 
abnormalities during hypoglycemia are the most common cause of 
arrhythmias among diabetic patients (1).  Ventricular tachycardia and 
fibrillation, atrial fibrillations are the common arrhythmias associated with 
hypoglycemia (3).  In our study hypoglycemia is more in Type 2 DM than 
Type-1. Prolongation of Q-T c is also more in type-2 DM.  Type-2 DM 
patients have additional risk factors like smoking, alcohol intake, systemic 
hypertension, obesity, that also responsible for sudden cardiac death in type-2 
DM(4).  In our study male having higher incidence of hypoglycemia 
compared to females. 
                   Among diabetes, type-1 DM patients have significantly increased 
in the frequency of hypoglycemic episodes compared to type-2.  Because 
Type-1 DM patients are dependent on insulin. Though Type-2 patients 
initially responding to oral hypoglycemic agents, later they require insulin or 
become insulin dependent, due to progression of disease. Around 50% of beta 
cells will be lost at the time of diagnosing Type-2 DM (11).  
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As the age advances with uncontrolled DM, Patients will require insulin for 
their survival (16).  Moreover duration of diabetes is also associated with 
prolongation of Q-T interval and sudden cardiac death (19). 
Glucose level: 
- In our study very low glucose level patients have higher 
incidence of Q-T prolongation. It is due to repolarization 
abnormalities more in severe hypoglycemia that precipitates 
arrhythmias.  
Sex: 
                 In our study 59 of males, 4 females developed hypoglycemia. 15 
males, 13 females had hypoglycemia below 30. Mortality is more below 50 
mg/dl. 
 Type of Diabetes mellitus: 
           In our study, 71 Type-2, and 29 Type-1 patients had   hypoglycemia. 
20 patients of Type-2, 8 patients of Type-1 had   severe hypoglycemia (<30). 
Q-T prolongation: 
                75 developed hypoglycemia in our study.  24 patients are falling 
between the blood sugar levels of 40-60 mg/dl. 51 patients developed 
hypoglycemia below the level of 40 mg/dl. 49 patients are Type-2 and 26 
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patients are Type –1. Incidence of Q-T prolongation is more below 40mg/dl 
with statistically significant (p.048) 
Arrhythmias: 
               In our study 10 patients developed Arrhythmias. There is no 
Arrhythmia between the levels of 40-60 mg/dl.   4 patients between the level 
of 40-80 and 6 patients below the level of 30 mg/dl developed Arrhythmias 
with statistically significant (p<0.016) chi square value-6.67. 
DEATH:  
 In our study one patient died due to Arrhythmia in blood sugar 
range of 40-30 mg/dl. 
 5 patients died, below the blood sugar level of 30 mg/dl with 
statistically significant p<0.047. 
Duration of diabetes: 
                In our study, as the duration of Diabetes increase.   Q-T 
prolongation also increase with statistically significant (p<0.001).Chi square 
=> 47.25.       
58 patients with 21-30 yrs of duration of diabetes, 14 patients with 11-20 yrs 
of duration of diabetes, 3 patients with 5-10 yrs of duration of diabetes 
developed QT prolongation.          
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                                      CONCLUSION 
   From our study we conclude, that     
1)  Incidence of QTc prolongation is more with severe 
hypoglycemia. 
 
2)  QTc interval more than 500millisecond causes Arrhythmia, 
thereby causing sudden cardiac death. 
 
 
3) Repolarization abnormality is the most common cause of 
arrhythmia in severe hypoglycemia (1). 
 
    4)  Deaths due to severe hypoglycemia are most common in type 2 Diabetes 
Mellitus patients.  
 
    5)  Duration of diabetes mellitus is also a risk factor for developing 
arrhythmia and sudden cardiac death (19) 
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LIMITATION OF THE STUDY: 
 
                                             This study has its own limitation. The number of 
patients in this study is small. Hence generalization of results of the study 
have to be made with caution. 
 
                                              The study population involved patients seeking 
medical care in our hospital which is a tertiary care center and hence they may 
not represent the general population 
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                          PROFORMA 
 
Name:                       Age/Sex: Occupation: 
 
Presenting complaints: 
 H/o palpitation, H/o sweating, H/o giddiness, H/o chest pain, H/o 
tremor, H/o confusion, H/O seizure, H/o headache, 
Past History: 
H/o DM, HT, CKD, CVD, DRUG INTAKE, CAD. 
Clinical Examination: 
General Examination: 
 Consciousness, Pallor, jaundice, Clubbing, Lymphadenopathy, 
hydration status 
Vitals: PR, BP, RR, SpO2. 
Systemic examination: CVS: RS: ABDOMEN: CNS: 
 
 
Laboratory investigations: 
 RBS (Venous blood sample for glucose analysis) 
Sr. Electrolytes and Sr.Calcium 
ECG 
Echocardiogram 
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               ABBREVIATIONS 
 
DM                       Diabetes Mellitus 
ADA                     American Diabetes Association 
MODY                 Maturity Diabetes Onset of Young 
GAD                    Glutamic Acid Decarboxylase 
C-RP                    C - reactive protein 
MRDM                Malnutrition Related Diabetes Mellitus 
FCPD                   Fibro Calculus Pancreatic Diabetes 
PDDM                 Protein deficient diabetes mellitus 
IGT                      Impaired Glucose Tolerance 
IFG                      Impaired Fasting Glucose 
DKA                   Diabetic keto Acidosis 
OGTT                 Oral Glucose Tolerance Test 
TNF                    Tumor Necrosis Factor 
VLDL                 Very Low DensityLipo Protein 
LDL                    Low DensityLipo Protein 
HDL                    High Density Lipo Protein 
LPL                     Lipo Protein Lipase 
AGE                    Advanced Glycosylated End Products 
PUFA                  Poly Unsaturated Fatty Acids 
MUFA                 Mono Unsaturated Fatty Acids 
VSMC                 Vascular Smooth Muscle Cells 
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MASTER 
CHART             
s.no name age sex 
type 
1 
DM 
type 2 
DM  
duration 
of DM  in 
years 
QTC 
prolongation arrythhmias DEATH stage 
QT 
interval(ms) 
1 Rengasamy  33 M       +           - 10       I 430 
2 Anthony samy 36 M       +           - 10       I 432 
3 Palpandi 39 M       +           - 5       I 432 
4 kuppammal 30 F       +           - 5 p     I 480 
5 Pitchai 31 M       +           - 5       I 440 
6 kalimuthu 38 M       +           - 10 p     I 465 
7 irulayee 36 F       +           - 10       I 455 
8 Yesudoss 39 M       +           - 8       I 440 
9 karupayee 40 F       +           - 10       I 450 
10 cristopher 40 M       +           - 10       I 432 
11 shajahan 39 M       +           - 11       I 432 
12 ajith 31 M       +           - 13 p     I 465 
13 balusamy 30 M       +           - 15       I 440 
14 arun 33 M       +           - 18 p     I 470 
15 muthusamy 34 M       +           - 18 p     I 472 
16 kuppan 41 M       +           - 20       I 428 
17 sadaiyan 46 M       +           - 20 p     I 476 
18 maruthupandi 47 M       +           - 20 p     I 465 
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19 periyakaruppan 49 M       +           - 20       I 420 
20 adiakavalam 41 M       +           - 19 p     I 468 
21 yekalaivan 49 M       +           - 15 p     I 462 
22 gopalakrishnan 44 M       +           - 15 p     I 460 
23 karupandi 46 M             - 10       I 420 
24 isaikitru 49 M       +           - 14 p     I 464 
25 shankar 50 M            + 14 p     I 468 
26 marimuthu 42 M            + 13       I 430 
27 kavirajam 43 M       -          + 18       I 430 
28 sangarappan 45 M       -          + 18       I 424 
29 sherif 45 M       -          + 19 p     II 481 
30 chinnasamy 44 M       -          + 19       II 426 
31 andisamy 76 M       -          + 20 p     II 485 
32 jegdish 60 M       -          + 20 p     IV 426 
33 gurusamy 60 M       -          + 28 p     IV 426 
34 syed 55 M       -          + 30 p     II 486 
35 vadivu 54 M       -          + 20 P     II 490 
36 mani 53 M       -          + 20 P     IV 424 
37 rahman 54 M       -          + 28 p     II 496 
38 ilangovan 56 M      -          + 20 P     II 482 
39 chinnu 59 M      -          + 28 p     III 506 
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40 ravindran 60 M      +          - 28 p     III 505 
41 azar ali 51 M      +          - 28 p p p III 520 
42 kasi 55 M      +          - 28 p p p IV 550 
43 pasupathi 54 M      +          - 28 p p p IV 548 
44 thavasi 55 M      +          - 24 p     III 510 
45 sankarapandi 59 M      +          - 24 p     III 512 
46 guru 60 M      +          - 22       II 420 
47 muthu 52 M      -          + 21       II 426 
48 ramaiah 54 M      -          + 21 p     II 481 
49 rajesh 55 M      -          + 21 P     II 482 
50 periyasamy 56 M      -          + 28 p     III 510 
51 murugan 55 M      -          + 24       III 504 
52 revathi 56 F      -          + 21       II 460 
53 rajathi 59 F      -          + 28 p p   IV 524 
54 aparna 52 F      +          - 21       III 458 
55 akshaya 55 F       -          + 17 p     II 460 
56 
senthamarai 
kannan 56 M       -          + 18 p     II 486 
57 anusuya 58 F       -          + 20 p     II 500 
58 anitha 58 F       -          + 11       II 454 
59 sindhuja 59 F       -          + 18       II 450 
60 sudha 60 F       -          + 22 p     II 496 
  
 
[119] 
 
61 suganya 54 F       -          + 22 p     III 512 
62 saranya 55 F 
       
+          - 21 p     III 510 
63 adhira 54 F 
       
+          - 23 p     III 508 
64 Karthiga 59 F 
       
+          - 24 p     III 510 
65 kamatchi 60 F 
       
-          + 24 p     III 505 
66 kavitha 60 F 
       
-          + 21 p     II 490 
67 karanya 55 F 
       
-          + 22 p     III 510 
68 sumalatha 53 F 
       
-          + 23       III 452 
69 maheshwari 52 F 
       
+          - 21 P     III 520 
70 madhavi 51 F 
       
+          - 24 p     II 482 
71 raja 52 M 
       
+          - 21 p     III 518 
72 ramu 55 M 
       
+          - 21 P     III 510 
73 seenivasan 54 M 
       
+          - 25 P     III 508 
74 prem 70 M 
       
+          - 30 p p p IV 545 
75 karthick 69 M 
       
+          - 28 p p p IV 544 
76 israth 61 M 
       
+          - 25 P     III 510 
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77 vijayaraja 65 M 
       
+          - 21 p     III 508 
78 chinnamariappan 64 M 
       
+          - 24 p     III 504 
79 
 shanmuga 
sundaram 63 M 
       
+          - 25 p     III 510 
80 naveen 62 M 
       
+          - 21 p     III 502 
81 sunitha 61 F 
       
+          - 25 p     IV 524 
82 leelavathy 69 F 
       
+          - 22 p     IV 526 
83 meena 68 F 
       
+          - 21 p     IV 526 
84 anu 67 F 
       
+          - 24 p     IV 526 
85 teenu 66 F 
       
+          - 25 p     IV 524 
86 manimekalai 65 F 
       
+          - 28 p     IV 528 
87 muthumari 70 F 
       
+          - 30 p     IV 526 
88 thamarai 70 F 
       
+          - 30 p     IV 524 
89 devi 65 F 
       
+          - 28 p     IV 524 
90 geetha 64 F 
       
+          - 25 p     IV 526 
91 ramya 63 F 
       
+          - 25 p     IV 524 
92 aarthi 65 F                 - 28 p p   IV 540 
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+ 
93 abinaya 64 F 
        
-          + 28 p p   IV 542 
94 akalya 65 F 
        
-          + 21 p     IV 522 
95 kupammal 62 F 
        
-          + 23 p     IV 524 
96 ambal 61 F 0          + 24 P     IV 524 
97 amsavalli 61 F 
        
-          + 25 p     IV 526 
98 revathi 70 F 
        
-          + 21 P     IV 524 
99 rajathi 62 F 
        
-          + 28 p p   IV 528 
100 premalatha 61 F 
        
-          + 30 p p p IV 540 
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